logo.png
  • googlePlaces
  • twitter
  • linkedin
  • Home

  • Team

  • Portfolio

  • Blog

  • Contact

  • Investors

    • MCPF I
    • MCPF II
    • Opportunity Fund
    • MCPF III
  • More

    Use tab to navigate through the menu items.

    Our Recent Posts

    Catalyst OrthoScience Announces Todd Wilson, PhD as Vice President of Medical Education & Training

    Real-world study of SPRINT Corroborates Published Clinical Study Results

    7SIGNAL Hires New Chief Technology Officer

    Archive

    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • December 2021
    • October 2021
    • September 2021
    • August 2021
    • June 2021
    • May 2021
    • April 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • July 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    SPR Therapeutics Announces FDA Clearance of an Expanded Indication for the SPRINT® PNS System

    SPR Therapeutics Announces FDA Clearance of an Expanded Indication for the SPRINT® PNS System

    SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral Nerve Stimulation (PNS) System. Prior clearance limited use of the SPRINT PNS System to the back and extremities, but the new indication allows the device to be used in areas of the head, neck, and the front of the torso. The clearance was based on real world safety data collected from over 5,500 patients using the SPRINT PNS Sy
    Redi.Health Named as a Top Startup to Watch in 2022 by Purpose Jobs

    Redi.Health Named as a Top Startup to Watch in 2022 by Purpose Jobs

    Purpose Jobs, a company that connects top talent with purpose-driven companies based on values, experience and culture contribution, has released their list of Top Columbus Startup and Tech Companies to Watch in 2022. We are thrilled to share that Redi.Health was included on this list. Read more about Redi's nomination to the list and the other exciting companies included here

     Follow us:

    • googlePlaces
    • twitter
    • linkedin

    Email us:

    Mutual Capital Partners

    1290 Bassett Rd  Suite #7

     Westlake, OH 44145

    MCPF@mutualcapitalpartners.com

    ©2021 by Mutual Capital Partners